Effect of Monoamine oxidase A (MAOA) inhibitors on androgen‐sensitive and castration‐resistant prostate cancer cells
- 28 January 2019
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 79 (6) , 667-677
Abstract
Background: Monoamine oxidase A (MAOA) is best known for its role in neuro‐transmitter regulation. Monoamine oxidase inhibitors are used to treat atypical depression. MAOA is highly expressed in high grade prostate cancer and modulates tumorigenesis and progression in prostate cancer. Here, we investigated the potential role of MAOA inhibitors (MAOAIs) in relation to the androgen receptor (AR) pathway and resistance to antiandrogen treatment in prostate cancer.Methods: We examined MAOA expression and the effect of MAOI treatment in relation to AR‐targeted treatments using the LNCaP, C4‐2B, and 22Rv1 human prostate cancer cell lines. MAOA, AR‐full length (AR‐FL), AR splice variant 7 (AR‐V7), and PSA expression was evaluated in the presence of MAOAIs (clorgyline, phenelzine), androgenic ligand (R1881), and antiandrogen (enzalutamide) treatments. An enzalutamide resistance cell line was generated to test the effect of MAOAI treatment in this model.Results: We observed that MAOAIs, particularly clorgyline and phenelzine, were effective at decreasing MAOA activity in human prostate cancer cells. MAOAIs significantly decreased growth of LNCaP, C4‐2B, and 22Rv1 cells and produced additive growth inhibitory effects when combined with enzalutamide. Clorgyline decreased expression of AR‐FL and AR‐V7 in 22Rv1 cells and was effective at decreasing growth of an enzalutamide‐resistant C4‐2B cell line with increased AR‐V7 expression.Conclusions: MAOAIs decrease growth and proliferation of androgen‐sensitive and castration‐resistant prostate cancer cells. Clorgyline, in particular, decreases expression of AR‐FL and AR‐V7 expression and decreases growth of an enzalutamide‐resistant cell line. These findings provide preclinical validation of MAOA inhibitors either alone or in combination with antiandrogens for therapeutic intent in patients with advanced forms of prostate cancer.Keywords
Funding Information
- Tsai Family Fund
This publication has 32 references indexed in Scilit:
- Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancerTherapeutic Advances in Urology, 2013
- MAO inhibitors: Risks, benefits, and loreCleveland Clinic Journal of Medicine, 2010
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variantJournal of Clinical Investigation, 2010
- Targeting monoamine oxidase A in advanced prostate cancerJournal of Cancer Research and Clinical Oncology, 2010
- Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cellsBMC Medical Genomics, 2009
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate CancerCancer Research, 2008
- The Significance of Monoamine Oxidase-A Expression in High Grade Prostate CancerJournal of Urology, 2008
- A molecular correlate to the Gleason grading system for prostate adenocarcinomaProceedings of the National Academy of Sciences, 2006
- Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663Journal of Clinical Oncology, 2003